Author/year [Ref.] | Line of treatment | Bevacizumab dose | No. of patients | Median PFS (m) | Median OS (m) | ORR (%) |
---|---|---|---|---|---|---|
 |  |  |  | HTN vs. No HTN | HTN vs. No HTN | HTN vs. No HTN |
Scartozzi M/2009[20] | First-line | 5Â mg/kg/2w | 39 | 14.5 vs. 3.1 | NA vs. 15.1 | 75% vs. 32% |
Rebekah/2009[21] | First-line | NA | 52 | NA vs. NA | NA vs. NA | NA vs. NA |
De Stefano/2011[19] | First-line | 5Â mg/kg/2w or 7.5Â mg/kg/3w | 74 | 15.1 vs. 8.3 | 35.5 vs. 26.7 | 84.6% vs. 42.6% |
Osterlund P/2011[17] | First- or second-line | 5Â mg/kg/2w | 101 | 10.5 vs. 5.3 | 25.8 vs. 11.7 | 52.6% vs. 45.5% |
Horinouchi Y/2011[18] | First-line | NA | 36 | 16.25 vs. 10 | NA vs. NA | 60% vs. 23.1% |
Dewdney A/2011[22] | First-line | 7.5Â mg/kg/3w | 45 | NA vs. NA | NA vs. NA | 71% vs. 78% |
Tahover E/2013[16] | First- or second-line | 2. 5Â mg/kg/w | 181 | 29.9 vs. 17.2 | NA vs. 36.8 | NA vs. NA |